Effect Of Interleukin-15 Stimulated NK-EVs And Carboplatin On Osimertinib-Resistant Lung Cancer Cells

Overcoming drug resistance in cancer treatment remains a significant challenge. This white paper explores a promising new approach to treating Osimertinib-resistant lung cancer, specifically focusing on H1975 cells with EGFR mutations. Our research investigates the combined therapeutic potential of interleukin-15 (IL-15) stimulated natural killer cell-derived extracellular vesicles (NK-EVs) and carboplatin (CBP).
We detail the isolation and characterization of NK-EVs, utilizing techniques such as ultracentrifugation, nanoparticle tracking analysis, and atomic force microscopy. Our findings confirm the presence of key exosomal markers and demonstrate the cytotoxic effects of NK-EVs on H1975R cells in both 2D and 3D cell cultures. Notably, combining NK-EVs with CBP significantly reduced CBP’s IC50, enhancing its efficacy. In vivo studies using H1975R tumor xenografts further validated these results, demonstrating a substantial reduction in tumor volume. This research uncovers the novel mechanism by which NK-EVs target the PD-L1/PD-1 checkpoint, inducing apoptosis and an anti-inflammatory response.
Discover how this innovative immunochemotherapeutic strategy offers a potential breakthrough in treating resistant cancers. Access the full white paper to delve into the detailed methodology, comprehensive results, and potential clinical implications of this groundbreaking research.
Get unlimited access to:
Enter your credentials below to log in. Not yet a member of Bioprocess Online? Subscribe today.